Back to News
Market Impact: 0.2
Perspective Therapeutics Consensus Price Target Decreased by 13.02% to $10.78
Source: Nasdaq
Analyst InsightsAnalyst EstimatesHealthcare & Biotech
The average one-year price target for Perspective Therapeutics (NYSEAM:CATX) was revised down 13.02% to $10.78 per share from $12.40, the prior estimate dated October 20, 2026. The figures are aggregate analyst targets; the article text provided is truncated.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
CATX-0.35
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Apple reports after the bell. Options traders expect a big move
- Mizuho lowers Lumentum stock price target on Marvell acquisition
- Why is Apple stock falling afterhours today?